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Abstract
BACKGROUND—Patients were recruited from the Dorothy P. and Richard P. Simmons Center
for Interstitial Lung Disease, located within the University of Pittsburgh Medical Center.
Idiopathic pulmonary fibrosis results in scarring of the lung and respiratory failure, and has a
median survival of 3 to 5 years from the time of diagnosis. The purpose of this study was to
determine whether patients with idiopathic pulmonary fibrosis and their care partners could be
more optimally managed by a disease-management intervention entitled “Program to Reduce
Idiopathic Pulmonary Fibrosis Symptoms and Improve Management,” which nurses delivered
using the format of a support group. We hypothesized that participation would improve
perceptions of health-related quality of life (HRQoL) and decrease symptom burden.
METHODS—Subjects were 42 participants randomized to an experimental (10 patient/care
partner dyads) or control (11 patient/care partner dyads) group. Experimental group participants
attended the 6-week program, and controls received usual care. Before and after the program, all
participants completed questionnaires designed to assess symptom burden and HRQoL. Patients
and care partners in the intervention group were also interviewed in their home to elicit
information on their experience after participating in the Program to Reduce Idiopathic Pulmonary
Fibrosis Symptoms and Improve Management.
RESULTS—After the intervention, experimental group patients rated their HRQoL less
positively (P = .038) and tended to report more anxiety (P = .077) compared with controls. Care
partners rated their stress at a lower level (P = .018) compared with controls. Course evaluations
were uniformly positive. Post-study qualitative interviews with experimental group participants
suggested benefits not exemplified by these scores. Patient participants felt less isolated, were able
to put their disease into perspective, and valued participating in research and helping others.
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CONCLUSION—Further exploration of the impact of disease-management interventions in
patients with advanced lung disease and their care partners is needed using both qualitative and
quantitative methodology. Disease-management interventions have the potential to positively
affect patients with advanced lung disease and their care partners.
Interstitial lung disease (ILD) is a condition that results in the progressive inability to
maintain normal blood oxygen levels because of impaired transfer of gas across the alveolar-
capillary membrane.1 More than 150 clinical diagnostic entities are associated with ILD.2,3
Idiopathic pulmonary fibrosis (IPF), also known pathologically as usual interstitial
pneumonia, is one of the most common forms of ILD. The prevalence of IPF has been
estimated to range from 4.0 per 100,000 persons aged 18 to 34 years to 227.2 per 100,000
persons aged ≥75 years.4 IPF is often viewed as having uniformly poor survival.4–7
However, the clinical course varies widely with some patients dying within 1 year of
diagnosis and others living much longer.8–12 The reason for this difference is unknown.8,12
There is currently no therapy that reverses or cures the lung damage.5,13 Lung
transplantation remains the only available treatment if the patient meets established
criteria.5,9
Patients diagnosed with IPF share problems common to any chronic illness, a life change
that can affect emotional response in a manner disproportionate to physical disability.14 As
with other chronic illnesses, the progressive disability associated with IPF affects both the
patient and the care partner. The emotional consequences can be particularly devastating,
given the lack of effective therapy. De Vries and colleagues15 reported that approximately
25% of patients with IPF experience depressive symptoms. The burden of illness is
commonly shared by a care partner who may also experience significant burden as the
illness progresses. For this reason, care partners have been termed “the hidden patient.”16
These findings and similar reports from other studies suggest potential benefit from an
intervention incorporating palliative care approaches for the patient and care partner.17–22
Although commonly integrated into the management of patients with cancer, the use of
palliative care is limited in patients with lung disease.23 The goal of palliative care is “to
prevent and relieve suffering and to support the best possible quality of life for patients and
their families, regardless of the stage of the disease or the need for other therapies.”24
Palliation may be the only therapeutic option for patients with advanced cancer, chronic
obstructive pulmonary disease, cystic fibrosis, and IPF.25 The concepts integral to palliative
care seem particularly appropriate for patients with IPF, whose mortality rate exceeds that of
many cancers.26
Although the stress of the diagnosis of a chronic medical illness typically induces anxiety
and depression, these symptoms may diminish if there is hope for a cure. When the
prognosis is unknown or the condition is likely to be terminal, anxiety and depression can
become more severe and prolonged.27 Patients with IPF face challenges to their functional
independence, self-esteem, and quality of life as a result of a progressive decrease in
exercise capacity. Activities of daily living require extra planning and time. “Cough
becomes a dreaded ordeal, and onset of exacerbations or new symptoms reawakens the fear
of respiratory crisis or death.”28 Faced with these stressors, patients with IPF are at high risk
for developing anxiety and depression. Because care providers typically focus on treatment
options, prognosis, and relief of physical discomfort, they may not actively solicit concerns
arising from anxiety and depressive symptoms from the patient or care providers.27
Studies have shown depression and anxiety are common in patients with chronic health
problems, but little research has been done in patients with IPF.28 Although anxiety and
depression are inevitable in patients with advanced lung diseases, both are highly responsive
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to treatment with medications and cognitive behavioral therapy.28 If depression and anxiety
are present, they are likely to affect health-related quality of life (HRQoL). Ratings of
HRQoL provide a means of quantifying, in a standardized manner, how chronic illness
affects daily life, health, and well-being.29,30 A limited literature has evaluated HRQoL in
patients with IPF.15,17,18,19,31,20,21,32,33 In these studies, patients with IPF consistently
demonstrated impaired HRQoL affecting both physical and psychologic function. Dyspnea
was an important factor influencing HRQoL,12 as was poor sleep quality34 and forced vital
capacity (FVC).12,15,17–22,31–35
Several studies have demonstrated that a psychoeducational intervention can benefit those
who have serious illness accompanied by stress and depression and can improve their
psychologic well-being.35–38 Although much of the literature focuses on those who
experience a long-term illness trajectory and their caregivers, the psychosocial impact of a
psychoeducational intervention targeted early in the onset of a potentially life-ending illness,
such as IPF, has not been examined.
The purpose of this study was to test the ability of the Program to Reduce Idiopathic
Pulmonary Fibrosis Symptoms and Improve Management (PRISIM) to decrease symptom
burden, decrease stress, and improve perceptions of HRQoL for patients with IPF and their
care partners. We hypothesized that, compared with usual care, the PRISIM intervention
would decrease symptom burden for patients and decrease stress and improve perceptions of
HRQoL for patients and caregivers.
MATERIALS AND METHODS
Design
This study used a quantitatively driven, concurrent nested mixed-method design with the
experimental group receiving the (PRISIM) intervention and the control group receiving
usual care only. The study enrolled 42 participants. Ten patient/care partner dyads were
randomized to the intervention group, and 11 patient/care partner dyads were randomized to
usual care. All patients/care partners completed questionnaires designed to measure anxiety,
depression, perceived stress, and HRQoL before and after completion of the intervention.
Patients completed a questionnaire to assess dyspnea at the same intervals. In addition,
patient/care partners randomized to the intervention group were interviewed in their homes
after completion of the intervention.
Participants were randomized to group after baseline questionnaires were completed. A
permutated blocked design was used to ensure that equal numbers of patients with moderate
(FVC 55%–70% predicted) and severe (FVC < 55% predicted) disease were assigned to
each group. The study received institutional review board approval, and all participants
provided informed consent.
Setting and sample
Patients were recruited from a university-based ILD program. Patients were required 1) to
be aged more than 21 years; 2) to be able to read and understand English; 3) to be diagnosed
with IPF; and 4) to have an FVC reflecting moderate (FVC 55%–70% predicted) or severe
(FVC < 55% predicted) disease. Care partners were required 1) to be aged more than 21
years; 2) to be able to read and understand English; and 3) to live with or care for the patient
with IPF. Both patient and care partner had to consent to study participation. Because the
study was designed to obtain pilot data for a future study, sample size was not based on a
power calculation.
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The intervention consisted of 6 weekly group sessions attended by patients and care
partners. The content for the sessions was developed collaboratively by a pulmonary clinical
nurse specialist whose practice involved patients with IPF, a psychiatric clinical specialist
with training as a cognitive behavioral therapist, and an advanced care planning instructor.
The sessions included the following: “What is IPF and How to Live with it?” (Session 1),
which reviewed the causes, pathophysiology, and treatment of IPF; “Gaining Control of
Your Moods and Feelings: You Feel the Way You Think” (Session 2), which discussed
basic principles of cognitive behavior techniques and cognitive distortions; “Gaining
Control of Your Moods and Feelings: What Can You Do about Depression” (Session 3),
which discussed concepts of stress and depression and interrelationships with illness;
“Putting Your Life in Order: What Do I Do Now?” (Session 4), which addressed planning
for uncertainty and concerns related to terminal illness, communicating with clinicians,
coping, and planning to one’s affairs; “Living with IPF” (Session 5), which discussed
symptom management, energy conservation, oxygen therapy, and the importance of
exercise; and “Wrap-up and Review Group” (Session 6), which focused on informal
discussion and review. Each session lasted 2 hours. Both groups received a copy of the book
Feeling Good: The New Mood Therapy39 to read at leisure (controls) or use in group
exercises (experimental group).
Patients randomized to usual care were seen by members of the clinical care team consisting
of a pulmonary clinical nurse specialist and physicians with expertise in the management of
IPF, typically at intervals of every 3 to 6 months. The pulmonary clinical nurse specialist
was available by phone to answer questions and conducted a monthly support group for
those wanting to attend. Psychologic counseling was provided, if indicated, but was not
offered on a routine basis.
Instruments
Dyspnea was measured using the University of California at San Diego Shortness of Breath
Questionnaire,40 which asked subjects to rate severity of shortness of breath on a 6-point
scale (0 = not at all to 5 = maximal or unable to do) during 21 activities of daily living
associated with varying exertion. Scores were obtained by summing responses on all items
(range 0–120). Internal consistency and validity have been well established.40
Anxiety was measured using the Beck Anxiety Inventory (BAI), a standardized, 21-item
tool41 that uses a 4-point scale (0 = absent/not at all disturbing to 3 = I could barely stand it)
to measure anxiety. Scores were obtained by summing the 21 items (range 0–63). A score of
0 to 7 indicated no anxiety, 8 to 15 indicated mild anxiety, 16 to 25 indicated moderate
anxiety, and greater than 26 indicated severe anxiety.41 Reported mean scores for
psychiatric outpatients with anxiety disorders range from 17 to 29,42 and means for
community samples ranged from 7 to 11. Reliability and validity have been well
established.43
Depression was measured using the Beck Depression Inventory-II (BDI-II),44 a 21-item
well-validated self-report instrument designed to measure the severity of depression in
adults and adolescents 13 years or older.44 The BDI-II is a revised version of the original
instrument. A score of 0 to 13 suggests minimal depression, 14 to 19 suggests mild
depression, 20 to 28 suggests moderate depression, and 29 to 63 suggests severe
depression.45 Reliability and validity have been well established.44
The Perceived Stress Scale46 was designed to measure the degree to which subjects find
their lives unpredictable, uncontrollable, and overloading. Respondents were asked to
indicate how they feel or thought in the last month using the option 0 (never) to 4 (very
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often). Total scores range from 0 to 40, with higher scores indicating more stress. Internal
consistency and validity have been well established with a diverse population.47–49
HRQoL was measured using the Short Form (SF)-36 (Version 2), a widely used generic
scale.18,50 Scores range from 0 (maximum impairment) to 100 (no impairment). The 8
domains can be grouped into a physical score that includes physical functioning, role
physical, bodily pain, and general health, and a mental score that includes vitality, social
functioning, role emotional, and mental health.51 The physical score and mental score were
normalized to responses from the general population (mean score = 50). Validity and
reliability have been well demonstrated.52
The battery required approximately 1 hour to complete. Demographic data were obtained
from the patient and care partner. Diagnosis and the most recent pulmonary function value
(FVC) were obtained from the medical record. Pulmonary function tests were obtained at 3-
to 6-month intervals or more frequently, if indicated.
Interviews
Each member of the experimental group dyad was interviewed separately in their home by
one member of the research team (KOL) after completion of the intervention. These
interviews were open-ended, for example, “tell me about participation in the PRISIM
intervention,” which allowed for data collection that reflected the perspectives of each
member of the dyad regarding their experience. Responses guided future questions and
became more focused as the interviews progressed. Qualitative methods were incorporated
into the study to address the conflicting results in the quantitative portion of the study. We
were interested in learning what explained the finding that the intervention had a negative
impact on the patients, but a positive impact on the care partners.
DATA ANALYSIS
Quantitative analysis
Baseline demographic and medical profile data were compared using chi-square and t tests,
as appropriate. Because differences in intervention and control groups were found in
baseline scores for anxiety and the physical aspect of HRQoL, questionnaire responses were
analyzed using analysis of covariance (ANCOVA). Theoretically, baseline differences
should not occur with randomization. Because such differences were present, ANCOVA
was used to control for these initial differences. The Statistical Package for the Social
Sciences v14.0 (SPSS Inc, Chicago, IL) was used for all data analyses. A P value of less
than .05 was chosen to indicate statistical significance.
Qualitative analysis
Verbatim transcripts were analyzed line by line initially and then more generally by a
qualitative research expert (EO). Data analysis consisted of open coding, wherein codes or
concepts were developed that reflected the meaning in the transcripts. These codes were
then analyzed through a process referred to as axial coding. Eventually, using a process
referred to as selective coding, only certain codes were determined to be supported by the
ongoing data collection, and those codes were then analyzed in more depth and integrated
into an explanatory framework.
Findings
Of the 42 subjects, 2 patients and 3 care partners did not complete data collection. Two
dyads did not continue because the patient died or received a lung transplant. The third care
partner failed to return after randomization. All were enrolled in the control group. Reasons
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for attrition were lung transplantation and death. Data are reported for the remaining 37
participants (Table I). No statistically significant differences were found between the
intervention and the control group in regard to demographic variables or FVC. The majority
(58%) of patients had scores indicating mild to severe anxiety, compared with 21% of care
partners. Four patients reported scores consistent with mild depression (n = 2) or moderate
(n = 2) depression; all were currently receiving treatment. No care partners reported
depressive symptoms.
Patient response
When post-intervention comparisons were made using ANCOVA, there were no statistically
significant differences in mean scores on the Shortness of Breath Questionnaire (P = .972),
Perceived Stress Scale (P = .531), BDI (P = .894), or SF-36 Mental Component (P = .772)
(Table II). The mean difference for BAI scores approached statistical significance (P = .077)
(Fig 1). Mean scores for the SF-36 physical component exhibited a statistically significant
difference (P = .038), reflecting lower (more negative) scores for intervention patients (Fig
2). Thus, contrary to expectations, findings suggested a negative impact of the intervention
on perceptions of physical HRQoL and a tendency for greater anxiety.
Care partner response
When post-intervention comparisons were made using ANCOVA, there were no statistically
significant differences between the intervention group and the control group for mean scores
on the BAI (P = .260), BDI (P = .751), SF-36 Physical (P = .669), or SF-36 Mental (P = .
565). Mean scores on the Perceived Stress Scale were significantly lower (P = .018) for the
intervention group (Fig 3). Thus, findings suggested no impact on anxiety, depressive
symptoms, or HRQoL, but a positive impact on perceived stress.
Qualitative analysis
The interviews included 19 experimental group participants. One care partner was
interviewed alone because the patient died before scheduling. Three common themes
emerged (Table III). Participants in PRISIM “didn’t feel isolated,” felt “able to put my
disease into perspective,” and “felt it was important to participate in research to help others.”
They recognized “you aren’t the only one that has a problem” which “gave comfort” and
provided an “improved mental picture.” PRISIM was viewed as “very beneficial” and led to
perceptions that one was “not as bad off as you think you are.” There was also a sense that
participation “might help us and maybe we could help somebody else.”
DISCUSSION
To our knowledge, this study is the first to test the ability of an intervention to decrease
symptom burden and improve perceptions of HRQoL for patients with IPF and their care
partners. Contrary to expectations, ratings of physical HRQoL were more negative at the
conclusion of the intervention and tended to reflect more anxiety. As anticipated, care
partners in the intervention group experienced less stress after participation in PRISIM.
Although these findings suggested increased distress, participants repeatedly voiced
appreciation for being able to participate in PRISIM. Qualitative themes supported feelings
of less isolation, a more balanced view of the illness, and personal satisfaction from being
able to participate in research. Although there was some increase in distress, there were also
benefits.
This outcome is perhaps not surprising. PRISIM was constructed to assist in coping with
depressive symptoms and encourage end-of-life decision-making, as well as increase
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knowledge of the disease. Although it is possible to avoid such discussions, the potential
rapid progression of IPF suggests that a more proactive approach is necessary. Nine months
after study entry, 7 patients (33%) had received lung transplants and 6 patients (29%) had
died.
When faced with a terminal illness or a life-changing event such as a lung transplant, frank
disclosure can encourage discussion regarding terminal care preferences.53 Unfortunately,
such discussions are often avoided.54,55 From a study of 105 patients with chronic
obstructive pulmonary disease, Heffner and colleagues55 reported that most patients (94.3%)
expressed worries about their health, although few (42%) had completed an advance
directive. Although most (98.9%) wanted discussions about end-of-life decision-making,
few (19%) had such discussions and few (14.3%) thought their physician understood their
preferences. As a consequence, patients were left to wonder what they might experience and
clinicians were without clear knowledge of their preferences. Not discussing such issues can
lead to distress that may not be recognized. Our findings reinforce the importance of directly
addressing such topics and carefully listening to the patient and care partner.
Hopwood and Stephens56 studied psychologic distress in patients with advanced lung cancer
and reported a prevalence of the affective disorder varying from 23% to 47%. Depression
was found in patients with more advanced stages of malignancy, more severe illness, and
poorer physical status. Patients with lung cancer are similar to patients with IPF in regard to
their prognosis and limited life expectancy. In 41 patients with IPF, De Vries and
colleagues15 reported that approximately 25% experienced depressive symptoms. Our
sample reported a lower incidence. This finding was potentially influenced by the support
available to all patients, including a clinical nurse specialist, support group, and active
research program.
Cognitive behavioral techniques have been widely used to managed depressive symptoms
after a diagnosis of Alzheimer’s,57,58 end-stage lung disease,58 arthritis,59 or coronary artery
disease,58 and in older adults.10 Cognitive behavioral interventions can benefit those who
experience major depression, as well as those who experience depressive symptoms and
anxiety.50,60 Patients with recurrent depression who were maintained at the same dose of
their antidepressant medication, but received 6 cognitive therapy sessions, had a lower
relapse rate than those who only had their antidepressant medication dose increased and did
not receive cognitive therapy.60 The Program to Encourage Active, Rewarding Lives of
Seniors study, which tested a cognitive behavioral intervention in patients with minor
depression, found that patients who enrolled in the program had a 50% reduction in
depressive symptoms, 43% had complete remission from depression, and 36% had improved
HRQoL.61 No studies were identified that studied the impact of cognitive behavioral
techniques in patients with IPF.
On the basis of qualitative data, the main benefits of PRISIM seemed to relate to feeling less
isolated and better able to view IPF and its symptoms in perspective. The instruments
selected to measure study outcomes focused on changes in symptom burden, perceived
stress, and HRQoL and may not have captured changes that occurred as a result of the
intervention. As an example, we did not measure self-efficacy (confidence) in dealing with
this illness. It is possible that findings regarding the intervention would have differed if the
study included different outcome measures or a longer follow-up interval. A longer follow-
up was not judged feasible because 9 months after study entry, 7 patients had received lung
transplants and 6 patients had died.
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The study was conducted to obtain pilot data for a future study, the sample size was small,
and the study was underpowered to detect a difference between groups. Findings need to be
confirmed in a larger sample. The requirement to attend multiple sessions was a barrier to
recruitment, and an Internet-based intervention may have been more appealing. However,
our format had the advantage of promoting discussion among participants and group leaders.
Of note, some of the participants traveled 2 to 3 hours to attend the session. Participants
were recruited from a center that specialized in management of patients with ILD. Both
groups therefore likely received support/education although not in the same intense manner.
Patients with IPF or their care partners without access to such support may have responded
differently to the intervention. Because of variability in disease progression and time since
onset of symptoms and referral, patients were assigned to a group on the basis of disease
severity, rather than time since diagnosis. Using time since diagnosis as the basis for group
assignment may have resulted in a different outcome. The rapid progression of IPF also
served as a limitation. Nine months after study entry, 13 patients (62%) either received lung
transplants or died. This outcome reinforces the need to develop interventions that prepare
patients for end-of-life decision-making and dealing with symptom burden but limited our
ability to conduct a more extended evaluation of the program.
CONCLUSIONS
PRISIM was innovative in its attempt to combine information about disease management
with information included in palliative care programs and strategies designed to elicit
discussion of preferences in end-of-life decision-making. The program enrolled the care
partner and patient in an attempt to enhance sharing on difficult to discuss topics. Although
questionnaire responses indicated the intervention tended to negatively affect participants,
qualitative data suggested positive benefits. Further exploration of the impact of disease-
management interventions in patients with advanced lung disease and their care partners is
needed using both qualitative and quantitative methodology.
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Change in patient’s pre- and post-intervention scores for BAI.
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Change in patient’s pre- and post-intervention scores for SF-36 Physical Component Score.
HRQoL = health-related quality of life.
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Change in care partner’s pre- and post-intervention scores for the Perceived Stress Scale.
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Table II
Adjusted mean scores reflecting symptom burden, stress, and perceptions of health-related quality of life by
intervention and control group participants (n = 37)a
Patients Care partners
Intervention Control Intervention Control
SOBQ 49.51 ± 22.64 49.88 ± 22.64
Beck Anxiety 15.13 ± 6.92 8.56 ± 6.95 2.22 ± 4.28 4.72 ± 4.32
Beck Depression 9.71 ± 4.34 9.44 ± 4.35 4.33 ± 3.29 4.84 ± 3.29
Perceived Stress 19.32 ± 3.64 18.20 ± 3.65 17.61 ± 2.68 20.99 ± 2.69
SF-36 Physical 31.06 ± 4.61 36.04 ± 4.63 50.12 ± 5.72 51.31 ± 5.72
SF-36 Mental 55.98 ± 2.71 55.61± 2.71 50.52 ± 1.67 50.05 ± 1.67
SOBQ, Shortness of Breath Questionnaire; SF-36, Short Form-36.
a
Values are mean ± standard deviation.
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